Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

JULY 24, 2021

“At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

AUGUST 2, 2021

capital markets, negative global economic conditions, potential negative developments in our clinical trials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co.,

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Forward-looking statements.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

The Cannigma

MAY 19, 2021

Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.

Law 137

Law Legalization Clinical Trials CBD 137

Cannabis Law Report

AUGUST 17, 2021

Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial. percent in patients on concomitant everolimus and 25.0 Conference Call and Webcast Details.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Altasciences helps sponsors get better drugs to the people who need them, faster. Christopher M.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. Logo – [link]. SOURCE SciSparc Ltd.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Project CBD

MAY 3, 2023

Dr. Goldstein: We don’t have clinical trials to say, yes this is definitively beneficial or detrimental for children. But we may be on the cusp of having those trials, which would be very exciting. CannMed: I’m glad you brought up ADHD. Full disclosure: my son has been diagnosed with ADHD.

Cannabinoids 213

Cannabinoids Sleep Clinical Trials CBD 213

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. In 2018, ProCon.org has estimated well over 3.5M

Events 48

Events THC Chronic Pain Sleep 48

Cannabis Law Report

JULY 28, 2021

However, prior to committing to a substantial clinical program for that indication, PharmaDrug looked to further expand on the body of existing supportive data for esophageal cancer, while also potentially revealing new, promising cancer indications. ” Next Steps. Cepharanthine’s Rationale in Cancer.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

Cannabis Law Report

JUNE 4, 2021

Clinical trial information: NCT03276572 ( [link] ). The full ASCO meeting program is available at: www.asco.org. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. About AIkido Pharma Inc.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

SEPTEMBER 2, 2021

– Company’s safeCircle™ Testing Program to Monitor for COVID-19 Among On-Campus Unvaccinated Populations –. Under the Contract, ADCL will deploy safeCircle™, its high-throughput, pooled COVID-19 testing program, to provide cost-effective COVID-19 testing. STONY BROOK, N.Y.–(BUSINESS

Clinical Trials 76

Clinical Trials Therapy Research and Development Collective 76

Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” 31, 2021. and 43 international patent-pending applications.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Patients 70

Patients Research and Development Clinical Trials Chronic Pain 70

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Adverse events were mostly mild and resolved spontaneously.

Chronic Pain 58

Chronic Pain Clinical Trials Marijuana Safety 58

Cannabis Law Report

OCTOBER 12, 2021

Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a pooled COVID-19 testing program that is grounded in the Company’s EUA-authorized Linea™ COVID-19 Assay Kit. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Programs 40

Programs Clinical Trials Research and Development Therapy 40

Cannabis Law Report

AUGUST 3, 2021

The Contract specifies ADCL’s deployment of safeCircle™, its high-throughput, pooled COVID-19 testing program, to provide weekly asymptomatic diagnostic COVID-19 screening of on-campus unvaccinated students, staff, and faculty, and a random sampling of vaccinated individuals across the CUNY school system.

Clinical Trials 81

Clinical Trials Therapy Collective Research and Development 81

Puff Puff Post

SEPTEMBER 16, 2019

Santé Cannabis, a pioneer in medical cannabis in Québéc , has partnered with Spectrum Therapeutics, the medical division of Canopy Growth (TSX: WEED) (NYSE: CGC) to launch the Prescriber Training Program, designed to aid physicians and patients, announced today at the new Santé Cannabis clinic and research centre in Montréal.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

JANUARY 13, 2020

In particular, we see significant market opportunity for nabiximols in several indications in the US and will be progressing multiple late stage clinical programs in 2020.”. Commence clinical program to expand future label to include spasticity associated with Spinal Cord Injury. Commence clinical program in PTSD.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Cannabis Law Report

JUNE 2, 2021

Aggregate testing results will be reported to the director of the summer camp via safeCircle’s integration with CLEARED4, the Company’s pooled surveillance testing program partner, through CLEARED4’s smartphone-based online health safety management and reporting solution. Testing will be conducted from mid-June through end-July.

Clinical Trials 63

Clinical Trials Therapy Collective Research and Development 63

Cannabis Law Report

JANUARY 26, 2022

The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

MAY 29, 2022

The grand opening event and reception invited investors, stakeholders and the residents of Princeton to take a tour through the facilities. The psilocybin mushrooms are headed to clinical trials, drug companies and medical facilities. “I’m The potential for psilocybin is untouched.”.

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. In August Anebulo formed the SAB to advise the Company on its clinical development programs and product pipeline. The founding co-chairs are Andrew Monte, M.D., and Arjun Chanmugam, M.D., both recognized leaders in emergency medicine.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

SpeedWeed

AUGUST 16, 2021

and industry-leading Cannabis Business Times, Cannabis Dispensary, and Hemp Grower magazines, announces today President of Scottsdale Research Institute (SRI) Sue Sisley, MD, as the keynote speaker on Day 2 of its annual event, to take place Aug. 24-26, 2021, at Paris Las Vegas Hotel & Casino. 25 from 11 a.m. – 24-26, 2021.

Media 52

Media Clinical Trials DEA Hemp 52

SpeedWeed

JULY 6, 2021

This new program is being funded by private investors, including Matt Wullenweg, developer of WordPress, and philanthropist Tim Ferriss. Professor Marks also serves on the Oregon Psilocybin Advisory Board, an agency tasked with overseeing the country’s first legal therapeutic psilocybin program.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

JUNE 7, 2021

NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. Hurry, 917-733-5573, sanjay.hurry@adnas.com Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com Web: www.adnas.com Twitter: @APDN.

Clinical Trials 49

Clinical Trials Research and Development Therapy Supply Chain 49

Cannabis Law Report

JANUARY 6, 2022

Anderson will be responsible for Anebulo’s global investor relations and public relations programs. Mr. Anderson will build on Anebulo’s current investor relations and public relations programs to grow and diversify the Company’s shareholder base as well as to enhance its communications with shareholders and other stakeholders.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. The MDMA Therapy Training Program was created to train the next generation of psychedelic therapists. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

OCTOBER 17, 2019

The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

Cannabis Law Report

FEBRUARY 10, 2022

Psilocybin’s therapeutic benefits are so promising that Denver, Colorado became the first city to decriminalize psilocybin in May 2019, and in 2020, Oregon passed Measure 109, which paved the road for a program allowing for legal manufacture, delivery, and administration of psilocybin to clients at supervised, licensed facilities in the state.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 40

Clinical Trials Research and Development Therapy Supply Chain 40

Cannabis Law Report

MARCH 2, 2020

This renewed interest in psychedelics is being sparked by a pair of seemingly unrelated events. So, there’s no overarching reason to think psychedelics can’t be handled in the same manner, especially if a drug successfully completes a rigorous clinical trial program. Hundreds of other U.S.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59